{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:54:24Z","timestamp":1791024864072,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":761,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV). Treatment-na\u00efve HCV genotype 1 or 4 patients were randomized to double-blind treatment with oral mericitabine at a dosage of 500 mg twice-daily (BID) for 12 weeks (A), 1,000 mg BID for 8 (B) or 12 weeks (C and D), or placebo BID for 12 weeks (E). All patients received pegylated interferon alpha-2a (Peg-IFN\u03b1-2a; 40 kD)\/ribavirin (RBV) at standard doses for 24 or 48 weeks during and after mericitabine\/placebo therapy. Patients in arms A-C who maintained a virologic response (VR) (HCV RNA &lt;15 IU\/mL) from weeks 4 to 22 stopped all treatment at week 24; all other patients (arms A-E) continued Peg-IFN\u03b1-2a\/RBV to complete 48 weeks. The primary outcome was sustained VR (SVR) (HCV RNA &lt;15 IU\/mL after 24 weeks of untreated follow-up; SVR-24). VR rates were higher in arms A-D than in arm E at weeks 4 and 12 overall, in patients with and without cirrhosis and in patients with CC and non-CC<\/jats:bold>\n                      <jats:bold>IL28B<\/jats:bold>\n                      <jats:bold>genotypes. However, the overall SVR-24 rate in arms D (50.6%) and E (placebo, 51.2%) was similar and those in the response-guided therapy arms A, B, and C were lower (48.8%, 42.0%, and 32.9%, respectively). No viral breakthrough or mericitabine-resistance mutations (S282T) were observed during mericitabine therapy.<\/jats:bold>\n                      <jats:bold>Conclusion<\/jats:bold>\n                      <jats:bold>: Treatment with mericitabine plus Peg-IFN\u03b1-2a\/RBV for 8 or 12 weeks provided potent suppression of HCV RNA, was well tolerated, and did not select resistant variants, but did not increase SVR rates, compared to placebo. IFN-free and IFN-containing trials of mericitabine of longer treatment duration are ongoing. (HEPATOLOGY 2013;58:524\u2013537)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.26274","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T11:05:13Z","timestamp":1359025513000},"page":"524-537","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":36,"title":["Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a\/Ribavirin Therapy in Treatment-Na\u00efVe HCV Genotype 1\/4 Patients"],"prefix":"10.1097","volume":"58","author":[{"given":"Heiner","family":"Wedemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mang-Ming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Rodriguez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Bzowej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Pockros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Lou","family":"Munson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Najera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thommes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20241201","doi-asserted-by":"crossref","first-page":"13351374","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R2-13-20241201","first-page":"245264","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection.","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"R3-13-20241201","doi-asserted-by":"crossref","first-page":"14331444","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"R4-13-20241201","doi-asserted-by":"crossref","first-page":"11951206","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"RU5-13-20241201","doi-asserted-by":"crossref","first-page":"12071217","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection.","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"RU6-13-20241201","doi-asserted-by":"crossref","first-page":"24052416","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"RU7-13-20241201","doi-asserted-by":"crossref","first-page":"10141024","DOI":"10.1056\/NEJMoa1014463","article-title":"Responseguided telaprevir combination treatment for hepatitis C virus infection.","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"RU8-13-20241201","doi-asserted-by":"crossref","first-page":"24172428","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection.","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R9-13-20241201","first-page":"S88S100","article-title":"Antiviral strategies in hepatitis C virus infection.","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J Hepatol"},{"key":"R10-13-20241201","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1177\/095632020601700203","article-title":"Inhibition of hepatitis C replicon RNA synthesis by betaD2deoxy2fluoro2Cmethylcytidine: a specific inhibitor of hepatitis C virus replication.","volume":"17","author":"Stuyver","year":"2006","journal-title":"Antivir Chem Chemother"},{"key":"R11-13-20241201","first-page":"94899495","article-title":"Nonnucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition.","volume":"278","author":"Wang","year":"2003","journal-title":"J Biol Chem"},{"key":"R12-13-20241201","doi-asserted-by":"crossref","first-page":"10301037","DOI":"10.1002\/hep.24788","article-title":"Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).","volume":"55","author":"Guedj","year":"2012","journal-title":"Hepatology"},{"key":"R13-13-20241201","doi-asserted-by":"crossref","first-page":"2981229820","DOI":"10.1074\/jbc.M705274200","article-title":"Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor betaD2deoxy2fluoro2Cmethylcytidine (PSI6130) and identification of a novel active 5triphosphate species.","volume":"282","author":"Ma","year":"2007","journal-title":"J Biol Chem"},{"key":"R14-13-20241201","doi-asserted-by":"crossref","first-page":"3433734347","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI7851 and its diastereoisomer PSI7977.","volume":"285","author":"Murakami","year":"2010","journal-title":"J Biol Chem"},{"key":"R17-13-20241201","doi-asserted-by":"crossref","first-page":"24052416","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26274","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201308000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T09:15:37Z","timestamp":1733044537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201308000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26274","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717976477.793470825","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}